Sort   by:  
 Page size 
UnknownCirculating vascular endothelial growth factor (VEGF) as predictive factor of progression-free survival in patients with advanced chordoma receiving sorafenib: an analysis from a phase II trial of the french sarcoma group (GSF/GETO).
Not available
S-EPMC5342029 | biostudies-literature
UnknownSorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO).
Not available
S-EPMC4576908 | biostudies-literature
UnknownPrognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab: an ancillary study derived from a randomized clinical trial.
Not available
S-EPMC6180490 | biostudies-literature
UnknownREGOSARC: Regorafenib versus placebo in doxorubicin-refractory soft-tissue sarcoma-A quality-adjusted time without symptoms of progression or toxicity analysis.
Not available
S-EPMC5485075 | biostudies-literature
UnknownPhase I Study of a Combination of Fluvastatin and Celecoxib in Children with Relapsing/Refractory Low-Grade or High-Grade Glioma (FLUVABREX).
Not available
S-EPMC10093481 | biostudies-literature
Sort   by:  
 Page size